Ask AI
mCRPC Decision Support Tool
Interactive Decision Support Tool: Expert Treatment Guidance for Metastatic Castration Resistant Prostate Cancer

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: October 15, 2025

About This Tool & Disclaimer

Clinical Care Options, LLC, is grateful to Tanya B. Dorff, MD; Shilpa Gupta, MD; Rana R. McKay, MD, FASCO; Alicia K. Morgans, MD, MPH, FASCO; and Neal D. Shore, MD, FACS, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

This tool was created in October 2025 and reflects the guidelines available at that time.

The goal of this tool is to educate healthcare professionals (HCPs) on making optimal management choices for patients with metastatic castration-resistant prostate cancer (mCRPC). A series of questions allows the user to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include whether the prostate cancer is hormone sensitive or castration-resistant, and the presence or absence of metastases. Other considerations that are not included in the algorithm of this interactive tool, such as the presence of various comorbidities and any concurrent medications, should also be considered, when appropriate.

This tool assumes that the patient is an adult male diagnosed with mCRPC for whom systemic anti-mCRPC therapy is being considered or has started. The tool also assumes that there are no other features or specific comorbidities that would materially affect treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display expert recommendations for that specific patient case.

For additional information on best practices in the management of patients with mCRPC with a focus on radioligand therapies, please see our online module "Advances in Metastatic Castration-Resistant Prostate Cancer: Focus on Radioligand Therapies" by Tanya B. Dorff, MD and Phillip Kuo, MD.

This program is supported by an educational grant from Novartis.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Tanya B. Dorff, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Janssen, Novartis, Pfizer.

Shilpa Gupta, MD: consultant/advisor/speaker: Astellas, AstraZeneca, Bristol Myers Squibb, Foundation Medicine, Johnson & Johnson, Merck, Novartis, Pfizer; researcher: Amgen, Bristol Myers Squibb, Convergent Therapeutics, Flare Therapeutics, Merck, Novartis, Pfizer, Roche, Tyra Biosciences; individual publicly traded stock/stock options: BioNTech, Nektar Therapeutics.

Rana R. McKay, MD, FASCO: consultant/advisor/speaker: Ambrx, Arcus, AstraZeneca, Aveo, Bayer, Blue Earth Diagnostics, Bristol Myers Squibb, Calithera, Caris, Daiichi Sankyo, Dendreon, Exelixis, Johnson & Johnson, Lilly, Merck, Myovant, Neomorph, Nimbus, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, Tempus.

Alicia K. Morgans, MD, MPH, FASCO: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Curium, Dendreon, Exact, Exelixis, Lantheus, MacroGenics, Merck, Novartis, Pfizer, Sumitomo, Telix, Tolmar; researcher: Astellas, Bayer, Curium, Pfizer, Telix.

Neal D. Shore, MD, FACS: consultant/advisor: Alessa, Amgen, Asieris, Astellas, AstraZeneca, Aura Biosciences, Bayer, BioProtect, Bristol Myers Squibb, Daiichi Sankyo, Denderon, Ferring, Johnson & Johnson, Merck, Pfizer, Photocure, Tutelix.

© 2025 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, "Interactive Decision Support Tool: Expert Treatment Guidance for Metastatic Castration Resistant Prostate cancer" is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for treating patients with mCRPC. The information provided is based on guideline recommendations and expert guidance of Tanya B. Dorff, MD; Shilpa Gupta, MD; Rana R. McKay, MD, FASCO; Alicia K. Morgans, MD, MPH, FASCO; and Neal D. Shore, MD, FACS.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Decision Support Tool: Expert Treatment Guidance for Metastatic Castration Resistant Prostate cancer” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2025 Clinical Care Options, LLC. All rights reserved.

Program Content